The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Quanta Therapeutics Inc. has identified new pyrimidine-based GTPase KRAS G12D and G12V mutant inhibitors potentially useful for the treatment of cancer. BioWorld Science Cancer Patents Popular Stories ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from ... Revolution Medicines, Quanta Therapeutics, and Roche/Chugai. Mirati’s MRTX1133 is in phase ...

Silexion Therapeutics Corp. announced promising preclinical ... of cancer cell growth in pancreatic tumor cell lines with KRAS G12D mutations. Following previous successes with its first ...

Verastem (VSTM) announced it has exercised early the option to license from GenFleet Therapeutics VS-7375, an oral and selective KRAS G12D inhibitor. In addition, the company announced preliminary ...